Does Bactrim Treat Moraxella?
Yes, Bactrim (trimethoprim-sulfamethoxazole) has in vitro activity against Moraxella catarrhalis, but clinically significant resistance rates of up to 50% have been reported, making it a suboptimal choice for empiric therapy.
Key Clinical Considerations
Susceptibility Profile
While Moraxella catarrhalis is technically susceptible to trimethoprim-sulfamethoxazole in laboratory testing, the guideline evidence reveals a critical caveat: TMP-SMX resistance rates as high as 50% have been occasionally reported 1. This high resistance rate substantially undermines its reliability as a treatment option.
The 2011 European guidelines specifically note that despite nearly universal β-lactamase production in M. catarrhalis (making it resistant to amoxicillin and ampicillin), resistance to other antibacterial agents has developed, with TMP-SMX being particularly problematic 1.
FDA-Approved Indications
The FDA label for Bactrim does not list Moraxella catarrhalis among its approved indications 2. The approved respiratory indications include:
- Acute otitis media due to Streptococcus pneumoniae or Haemophilus influenzae
- Acute exacerbations of chronic bronchitis due to S. pneumoniae or H. influenzae
The absence of M. catarrhalis from this list is telling.
Research Evidence Confirms High Resistance
Multiple studies demonstrate problematic resistance patterns:
- A 2002 study found that M. catarrhalis was "highly resistant against Trimethoprim Sulfamethoxazole" 3
- A 2008 Finnish surveillance study monitoring 14,138 M. catarrhalis isolates found no statistically significant connection between TMP-SMX use and resistance, suggesting resistance is already widespread and endemic rather than usage-dependent 4
Preferred Alternatives
For M. catarrhalis infections, use β-lactam/β-lactamase inhibitor combinations (amoxicillin-clavulanate) or other enzyme-stable β-lactams, macrolides, or tetracyclines 1. These agents maintain excellent activity:
- Amoxicillin-clavulanate: All isolates remain susceptible
- Macrolides: Very active
- Tetracyclines: Very active
Clinical Bottom Line
While Bactrim may work against some M. catarrhalis strains in vitro, the combination of:
- High and unpredictable resistance rates (up to 50%)
- Lack of FDA approval for this indication
- Availability of superior alternatives with reliable activity
makes Bactrim an inappropriate choice for treating Moraxella catarrhalis infections in clinical practice. Choose amoxicillin-clavulanate or a macrolide instead.